Glaukos enrolls first patients in phase 2 dry eye, presbyopia trials
Click Here to Manage Email Alerts
Enrollment is underway in two phase 2 clinical trials for dry eye disease and presbyopia, according to press releases from Glaukos.
GLK-301, a topical cream containing pilocarpine designed to treat signs and symptoms of dry eye disease, will be evaluated in a multicenter, randomized, double-masked, placebo-controlled trial. One of three different dose levels of GLK-301 or placebo will be applied to the eyelids of approximately 200 patients with dry eye twice daily for 28 days, followed by a 14-day safety assessment period.
“We believe our iLution platform has the potential to address the major unmet need for patients suffering from dry eye disease and other chronic eye diseases by providing an effective, easy to administer, safe, dropless transdermal therapeutic,” Thomas Burns, Glaukos president and CEO, said in a release.
The presbyopia trial will evaluate the safety and efficacy of GLK-302, a topical eyelid cream containing pilocarpine. One of three different dose levels of GLK-302 or placebo will be administered to approximately 120 patients with presbyopia twice a day for 28 days.
Reference:
- Glaukos announces first patient enrolled in phase 2 clinical trial for presbyopia. https://investors.glaukos.com/investors/news/news-details/2022/Glaukos-Announces-First-Patient-Enrolled-in-Phase-2-Clinical-Trial-for-Presbyopia/default.aspx. Published Jan. 11, 2022. Accessed Jan. 12, 2022.
Read more about
Click Here to Manage Email Alerts